Synopsis
Synopsis
0
USDMF
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Akabar
2. Bifix
3. Ediston
4. Ercefuryl
5. Eskapar
6. Nifuroxazide-ratiopharm
7. P-hydroxybenzoic Acid (5-nitrofurfurylidene)hydrazide
8. Panfurex
9. Pentofuryl
10. Septidiaryl
1. 965-52-6
2. Nifuroxazid
3. Dicoferin
4. Diarlidan
5. Nsc-759261
6. Pm5li0p38j
7. Rc-27109
8. Mls000069620
9. Ercefuryl
10. 4-hydroxy-n-[(e)-(5-nitrofuran-2-yl)methylideneamino]benzamide
11. P-hydroxybenzoic Acid 5-nitrofurfurylidene Hydrazide
12. Nifuroxazide (inn)
13. Nifuroxazida
14. Nifuroxazidum
15. 4-hydroxy-n'-((5-nitrofuran-2-yl)methylene)benzohydrazide
16. 4-hydroxy-n-[(e)-(5-nitro-2-furyl)methyleneamino]benzamide
17. Ercefurol
18. Smr000058185
19. Nifuroxazide [inn]
20. Sj000287313
21. Benzoic Acid, 4-hydroxy-, 2-[(5-nitro-2-furanyl)methylene]hydrazide
22. Nifuroxazidum [inn-latin]
23. Nifuroxazida [inn-spanish]
24. Ccris 5490
25. Rc 27109
26. P-hydroxybenzoic Acid (5-nitrofurfurylidene)hydrazide
27. R.c. 27-109
28. Einecs 213-522-0
29. Unii-pm5li0p38j
30. Brn 1352180
31. Diaryl
32. Nifuroxazide [inn:ban:dcf]
33. Mfcd00079482
34. 4-hydroxy-n'-(5-nitrofurfuryliden)benzhydrazid
35. 5-nitro-2-furaldehyde P-hydroxybenzoylhydrazone
36. Prestwick_874
37. (nitro-5' Furfurylidene-2') Hydroxy-4 Benzhydrazide
38. Opera_id_40
39. (nitro-5' Furfurylidene-2') Hydroxy-4 Benzhydrazide [french]
40. Benzoic Acid, P-hydroxy-, (5-nitrofurfurylidene)hydrazide
41. Prestwick2_000555
42. Prestwick3_000555
43. Bspbio_000629
44. Nifuroxazide [mart.]
45. Nifuroxazide [who-dd]
46. Schembl542542
47. Schembl543480
48. Bpbio1_000693
49. Chembl244888
50. Schembl14608895
51. Chebi:94556
52. Chebi:135136
53. Hms1569p11
54. Hms2096p11
55. Hms3713p11
56. Nifuroxazide [ep Impurity]
57. Pharmakon1600-01505788
58. Nifuroxazide [ep Monograph]
59. Hy-b1436
60. Zinc7997719
61. Bdbm50396177
62. Nsc759261
63. S4182
64. Stk091243
65. Stl454990
66. Akos000483758
67. Ac-8713
68. Ccg-213989
69. Cs-4918
70. Db13855
71. Nsc 759261
72. As-13310
73. Bim-0014420.p001
74. Sbi-0014420.p002
75. Ab00513861
76. D07111
77. Ab00513861_02
78. Ab00513861_03
79. Nifuroxazide, Vetranal(tm), Analytical Standard
80. 965n526
81. A845610
82. W-100139
83. Brd-k68188368-001-03-7
84. 4-dydroxy-n-[(e)-(5-nitro-2-furyl)methyleneamino]benzamide
85. 4-hydroxy-n'-[(1e)-(5-nitro-2-furyl)methylene]benzohydrazide
86. Nifuroxazide, European Pharmacopoeia (ep) Reference Standard
87. 4-hydroxy-n'-[(e)-(5-nitrofuran-2-yl)methylidene]benzohydrazide
88. 4-hydroxy-n-[(e)-(5-nitrofuran-2-yl)methylidene]benzenecarbohydrazonic Acid
89. Benzoic Acid, 4-hydroxy-, [(1e)-(5-nitro-2-furanyl)methylene]hydrazide
Molecular Weight | 275.22 g/mol |
---|---|
Molecular Formula | C12H9N3O5 |
XLogP3 | 2.1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 3 |
Exact Mass | 275.05422040 g/mol |
Monoisotopic Mass | 275.05422040 g/mol |
Topological Polar Surface Area | 121 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 387 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Infective Agents
Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)
A - Alimentary tract and metabolism
A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents
A07A - Intestinal antiinfectives
A07AX - Other intestinal antiinfectives
A07AX03 - Nifuroxazide
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Nifuroxazide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nifuroxazide, including repackagers and relabelers. The FDA regulates Nifuroxazide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nifuroxazide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nifuroxazide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nifuroxazide supplier is an individual or a company that provides Nifuroxazide active pharmaceutical ingredient (API) or Nifuroxazide finished formulations upon request. The Nifuroxazide suppliers may include Nifuroxazide API manufacturers, exporters, distributors and traders.
click here to find a list of Nifuroxazide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nifuroxazide CEP of the European Pharmacopoeia monograph is often referred to as a Nifuroxazide Certificate of Suitability (COS). The purpose of a Nifuroxazide CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nifuroxazide EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nifuroxazide to their clients by showing that a Nifuroxazide CEP has been issued for it. The manufacturer submits a Nifuroxazide CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nifuroxazide CEP holder for the record. Additionally, the data presented in the Nifuroxazide CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nifuroxazide DMF.
A Nifuroxazide CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nifuroxazide CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nifuroxazide suppliers with CEP (COS) on PharmaCompass.
A Nifuroxazide written confirmation (Nifuroxazide WC) is an official document issued by a regulatory agency to a Nifuroxazide manufacturer, verifying that the manufacturing facility of a Nifuroxazide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nifuroxazide APIs or Nifuroxazide finished pharmaceutical products to another nation, regulatory agencies frequently require a Nifuroxazide WC (written confirmation) as part of the regulatory process.
click here to find a list of Nifuroxazide suppliers with Written Confirmation (WC) on PharmaCompass.
Nifuroxazide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nifuroxazide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nifuroxazide GMP manufacturer or Nifuroxazide GMP API supplier for your needs.
A Nifuroxazide CoA (Certificate of Analysis) is a formal document that attests to Nifuroxazide's compliance with Nifuroxazide specifications and serves as a tool for batch-level quality control.
Nifuroxazide CoA mostly includes findings from lab analyses of a specific batch. For each Nifuroxazide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nifuroxazide may be tested according to a variety of international standards, such as European Pharmacopoeia (Nifuroxazide EP), Nifuroxazide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nifuroxazide USP).
LOOKING FOR A SUPPLIER?